Evogene Reports Second Quarter and First Half 2013 Financial Results

Evogene Reports Second Quarter and First Half 2013 Financial Results

2013 achievements to date include successful field trial results, new collaboration and continued expansion of unique infrastructure supporting four market focusedoperating divisions

REHOVOT, Israel--(BUSINESS WIRE)-- Evogene Ltd. (TASE: EVGN), a leader in plant genomics underlying crop productivity for the food, feed and biofuel industries, today announced its financial results for the second quarter and half year ended June 30, 2013.


Ofer Haviv, Evogene's President and CEO, stated: "The second quarter of this year saw significant progress and achievements as we further broadened our unique discovery and validation capabilities supporting our four market focused operating divisions, and continued to successfully meet objectives for both our partnered and Evogene sponsored product programs."

Mr. Haviv continued, "During the first half of 2013, and in particular the second quarter, we significantly increased our activities devoted to strengthening the infrastructure and expanding product offerings in our two newest operating divisions, Evofuel and Ag-chemicals. Evofuel, whose mission is the development of second generation feedstock for biodiesel, is in the process of completing the third year of field trials for our advanced castor varieties in northeast Brazil. We remain on track in our efforts to introduce a commercially viable alternative feedstock for biodiesel based on castor seeds in Brazil and Argentina."

"With respect to Ag-chemicals, which is the focus of our newest operating division, we believe our computational biology capabilities and plant genomic knowledge provide us with a unique opportunity to address the growing need for new and innovative products that can overcome the growing resistance of weeds and other pests to available chemical solutions. During the past quarter, in preliminary discussions with several leading companies in this field, we received initial confirmation that others share our belief."

"In our two operating divisions targeted at improving seed traits, one focused on yield and abiotic stress tolerance and the other on biotic stress tolerance, we continue to successfully meet the discovery and product candidate objectives under our existing collaborations with leading seed companies and evaluate new collaborations. During the past quarter, we announced the signing of a yield and abiotic stress tolerance focused collaboration for rice with DBN, a leading Chinese biotechnology company. In the area of biotic stress, we were pleased to recently announce successful field trial results in our program with Rahan Meristem to develop banana varieties expressing tolerance to Black Sigatoka disease. In addition to the potential value of this specific achievement, these results, although initial, provide a strong validation of the applicability of our predictive computational biology and gene discovery capabilities to biotic stress conditions, in addition to yield and abiotic stress conditions."

"Looking forward, it is our belief that the increased use of high-end agriculture technologies to provide improved seeds and new ag-chemical solutions will be an absolute requirement in order to address the growing worldwide needs for food, feed and fuel. Therefore, with the constantly increasing recognition by leading agriculture companies worldwide of Evogene as a unique and attractive solution provider, we are very optimistic regarding the future for our company," concluded Mr. Haviv.

Revenues for the first six months ended June 30, 2013 were $8.9 million, compared to $8.3 million for the same period in 2012. Revenues for the second quarter of 2013 were $4.3 million, compared to $4.1 million reported for the same period in 2012. Revenues for the first half and the second quarter of 2013 consist primarily of research and development fees under the company's various collaboration agreements with seed companies.

Cost of Revenues consists of expenses incurred in support of our on-going collaborations with seed companies which provide, in addition to current revenues related to research and development fees, the potential for future milestone and royalty revenues. Cost of Revenuesfor the first six months ended June 30, 2013 was $4.7 million, compared to $4.5 million for the same period in 2012. Cost of Revenuesduringthe second quarter of 2013 was $2.5 million, compared to $2.4 million reported for the same period in 2012.

Research & Development expenses for the first six months ended June 30, 2013, which do not include expenses incurred in support of on-going collaborations, were $4.7 million, compared to $3.3 million for the same period in 2012. Research and development expenses for the second quarter of 2013 were $2.5 million, compared to $1.9 million reported for the same period in 2012. The increases for 2013 compared to 2012 primarily relate to significantly increased activities devoted to strengthening the infrastructure and expanding product offerings in Evogene's two newest operating divisions, Evofuel and Ag-chemicals, including establishment of dedicated computational platforms and related headcount. These increases for 2013 also relate to broadening the company's competencies in the area of biotic discovery.

Loss from ordinary operations for the first six months of 2013 was $2.1 million, compared to loss from ordinary operations of $1.1 million in the same period in 2012. Loss from ordinary operations for the second quarter of 2013 was $1.6 million, compared to loss from ordinary operations of $1.0 million in the same period in 2012. The increase in loss from ordinary operations is mainly due to the increase in R&D expenses, as described above

Total comprehensive loss for the first six months ended June 30, 2013, was $2.4 million, compared to a total comprehensive loss of $0.7 million for the same period in 2012. Comprehensive loss for the second quarter of 2013 was $1.9 million, compared to a comprehensive loss of $1.2 million for the same period in 2012. The increase of comprehensive loss is mainly due to the increase in loss from ordinary operations, as described above, and an increase in financial expenses, mainly due to a decrease in market value of marketable securities the Company holds.

As of June 30, 2013, Evogene had $50.5 million in cash, cash equivalents and short term marketable securities, compared to $55.1 million as of December 31, 2012.

About Evogene
Evogene is a world leading plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals, and seeds focusing on second generation feedstock for biodiesel. The Company's headquarters are located in Rehovot, Israel and is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN). For additional information, please visit Evogene.

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may","expects","intends", "anticipates","plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation,those risk factors contained in Evogene's reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

As of June 30,

As of
December 31,

2013

2012

2012

Unaudited

Audited

CURRENT ASSETS

Cash and cash equivalents

16,884

11,558

24,262

Marketable securities

33,657

30,643

30,868

Short-term bank deposits

-

10,600

-

Trade receivables

1,853

3,911

1,542

Other receivables

1,573

681

650

53,967

57,393

57,322

LONG-TERM ASSETS

Long term deposits

33

47

43

Plant, property and equipment, net

7,572

7,825

7,401

Other investment

365

-

-

Intangible assets, net

67

111

89

8,037

7,983

7,533

62,004

65,376

64,855

CURRENT LIABILITIES

Trade payables

1,873

1,299

1,416

Other payables

2,677

1,866

3,139

Liabilities in respect of grants from the Chief Scientist

528

493

733

Deferred revenues

3,968

4,374

4,211

9,046

8,032

9,499

LONG-TERM LIABILITIES

Liabilities in respect of grants from the Chief Scientist

3,101

2,947

2,918

Deferred revenues

2,539

6,027

4,168

Severance pay liability, net

19

9

11

5,659

8,983

7,097

SHAREHOLDERS' EQUITY

Share capital

103

100

102

Share premium

84,874

82,042

83,688

Put options

(7,764)

(7,764)

(7,764)

Reserve - transaction with a former controlling shareholder

1,156

1,156

1,156

Capital reserve for share-based payment transactions

7,273

7,021

7,058

Accumulated deficit

(38,343)

(34,194)

(35,981)

47,299

48,361

48,259

62,004

65,376

64,855

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

U.S. dollars in thousands (except share and per share data)

For the Six Months
ended June 30,

For the Three
Months
ended June 30,

For the
Year
ended
December
31,

2013

2012

2013

2012

2012

Unaudited

Audited

Revenues

8,934

8,287

4,318

4,087

17,072

Cost of revenues

4,688

4,483

2,458

2,404

9,552

Gross profit

4,246

3,804

1,860

1,683

7,520

Research and development, net

4,666

3,308

2,480

1,851

7,252

Business development

532

544

305

295

1,159

General and administrative

1,248

1,069

673

533

2,268

51

-

31

-

33

Total operating expenses

6,395

4,921

3,427

2,679

10,646

Operating loss

(2,149)

(1,117)

(1,567)

(996)

(3,126)

Financing income

776

510

317

-

972

Financing expenses

(911)

(57)

(598)

(114)

(89)

Financial Expenses for Revaluation of Liabilities to the Scientist, Net

(78)

(19)

(33)

(29)

(205)

Loss before taxes on income

(2,362)

(683)

(1,881)

(1,139)

(2,448)

Taxes on income

-

(52)

-

(52)

(74)

Comprehensive net loss

(2,362)

(735)

(1,881)

(1,191)

(2,522)

Basic and diluted net loss per Share (in US Dollars)

(0.06)

(0.02)

(0.05)

(0.03)

(0.07)

anImage
anImage



Evogene
Karen Mazor, Director, Public and Investor Relations
+972-54-2288039
karen.mazor@evogene.com

KEYWORDS: United States North America New York Middle East Israel

INDUSTRY KEYWORDS:

The article Evogene Reports Second Quarter and First Half 2013 Financial Results originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.